Results

6 records – page 1 of 1.

Opioid overdose prevention supplies available in publicly accessible locations

https://policybase.cma.ca/en/permalink/policy13703

Date
2017-08-23
Topics
Health care and patient safety
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
GC17-06
The Canadian Medical Association supports making naloxone and other opioid overdose prevention supplies available in publicly accessible locations.
Policy Type
Policy resolution
Date
2017-08-23
Topics
Health care and patient safety
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
GC17-06
The Canadian Medical Association supports making naloxone and other opioid overdose prevention supplies available in publicly accessible locations.
Text
The Canadian Medical Association supports making naloxone and other opioid overdose prevention supplies available in publicly accessible locations.
Less detail

Management of chronic pain in older adults

https://policybase.cma.ca/en/permalink/policy13705

Date
2017-08-23
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
GC17-07
The Canadian Medical Association supports increased approval and funding of pharmacologic options for the management of chronic pain in older adults.
Policy Type
Policy resolution
Date
2017-08-23
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
GC17-07
The Canadian Medical Association supports increased approval and funding of pharmacologic options for the management of chronic pain in older adults.
Text
The Canadian Medical Association supports increased approval and funding of pharmacologic options for the management of chronic pain in older adults.
Less detail

Antimicrobial stewardship and antimicrobial resistance surveillance

https://policybase.cma.ca/en/permalink/policy13710

Date
2017-08-23
Topics
Health care and patient safety
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
GC17-11
The Canadian Medical Association calls on the federal government to use Canada’s term as G7 President in 2018 to add antimicrobial stewardship and antimicrobial resistance surveillance as part of their agenda.
Policy Type
Policy resolution
Date
2017-08-23
Topics
Health care and patient safety
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
GC17-11
The Canadian Medical Association calls on the federal government to use Canada’s term as G7 President in 2018 to add antimicrobial stewardship and antimicrobial resistance surveillance as part of their agenda.
Text
The Canadian Medical Association calls on the federal government to use Canada’s term as G7 President in 2018 to add antimicrobial stewardship and antimicrobial resistance surveillance as part of their agenda.
Less detail

Psycho-active substances and the operation of motor vehicles and industrial equipment

https://policybase.cma.ca/en/permalink/policy781

Last Reviewed
2017-03-04
Date
1973-06-16
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Population health/ health equity/ public health
Resolution
GC73-50
That the membership of the Canadian Medical Association clearly inform its patients, and the general public at large, of the hazards associated with the operation of motor vehicles, industrial equipment, etc., while under the influence of psycho-active substances, especially alcohol and antihistamines, and particularly the combination of such substances.
Policy Type
Policy resolution
Last Reviewed
2017-03-04
Date
1973-06-16
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Population health/ health equity/ public health
Resolution
GC73-50
That the membership of the Canadian Medical Association clearly inform its patients, and the general public at large, of the hazards associated with the operation of motor vehicles, industrial equipment, etc., while under the influence of psycho-active substances, especially alcohol and antihistamines, and particularly the combination of such substances.
Text
That the membership of the Canadian Medical Association clearly inform its patients, and the general public at large, of the hazards associated with the operation of motor vehicles, industrial equipment, etc., while under the influence of psycho-active substances, especially alcohol and antihistamines, and particularly the combination of such substances.
Less detail

Adverse reactions between alcohol and drug products

https://policybase.cma.ca/en/permalink/policy805

Last Reviewed
2017-03-04
Date
1987-08-25
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
GC87-31
That the Canadian Medical Association urge appropriate agencies to adopt regulations and/or policies to ensure that warnings about the adverse interaction between alcohol and both prescription and non-prescription products be prominently displayed or distributed wherever alcohol and drugs are sold and/or dispensed.
Policy Type
Policy resolution
Last Reviewed
2017-03-04
Date
1987-08-25
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
GC87-31
That the Canadian Medical Association urge appropriate agencies to adopt regulations and/or policies to ensure that warnings about the adverse interaction between alcohol and both prescription and non-prescription products be prominently displayed or distributed wherever alcohol and drugs are sold and/or dispensed.
Text
That the Canadian Medical Association urge appropriate agencies to adopt regulations and/or policies to ensure that warnings about the adverse interaction between alcohol and both prescription and non-prescription products be prominently displayed or distributed wherever alcohol and drugs are sold and/or dispensed.
Less detail

Drug product substitution

https://policybase.cma.ca/en/permalink/policy806

Last Reviewed
2017-03-04
Date
1987-08-25
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
GC87-39
The Canadian Medical Association supports the position that: 1) a patient should have the right to choose either a generic or a brand-name prescription drug where both alternatives exist; and 2) a physician should have the right to order "no substitution" of a drug product he or she prescribes.
Policy Type
Policy resolution
Last Reviewed
2017-03-04
Date
1987-08-25
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
GC87-39
The Canadian Medical Association supports the position that: 1) a patient should have the right to choose either a generic or a brand-name prescription drug where both alternatives exist; and 2) a physician should have the right to order "no substitution" of a drug product he or she prescribes.
Text
The Canadian Medical Association supports the position that: 1) a patient should have the right to choose either a generic or a brand-name prescription drug where both alternatives exist; and 2) a physician should have the right to order "no substitution" of a drug product he or she prescribes.
Less detail

6 records – page 1 of 1.